Sponsored By

Diabeloop reveals 12-month achievements for its hybrid closed-loop DBLG1 System at the EASD Annual Meeting 2022.

Omar Ford

September 21, 2022

1 Min Read
IMG_2022-9-21-182841.jpg
Image courtesy of marcos alvarado / Alamy Stock Photo

Diabeloop reported on 12 months of use of its hybrid closed-loop DBLG1 System on a large, multi-country patient cohort. Data was presented at the

While Time in Range (70-180 mg/dL) still shows constant improvement, time spent in hypoglycemia stays significantly low. Users share how these clinical results, combined with a growing trust in the algorithm has led to fewer interactions with the device and improved quality of life.

In line with previously presented data, significant improvement in Time in Range is observed here in a much larger population. The cohort gathers 4,162 patients in five countries: Germany, Italy, Spain, The Netherlands, and Switzerland. TIR gain is 17.6% points over a year of real-life use. 

Another significant result is that this improvement in time spent in the target range is combined with a still extremely low occurrence of hypoglycemia: 0.2% < 54 mg/dL, 1.1% < 70 mg/dL. For the patients’ clinical picture and for their overall quality of life, this means less than 20 minutes per day spent in hypoglycemia, whereas the maximum accepted in the international recommendations is 60 minutes

“When initiating a treatment with DBLG1, it can be expected that the recommended outcomes (i.e., a TIR>70%, a TBR

About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like